Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Bal Pharma Ltd. demonstrates moderate growth and reasonable valuation metrics compared to its peers in the Pharmaceuticals & Drugs sector. While it shows potential in profitability, there are stronger performers in terms of growth and returns on equity. Companies like Dr. Reddy's Laboratories and Cipla are leading in profitability, while Bal Pharma is relatively stable but lacks exceptional metrics. However, it remains a viable option for investors seeking value in a competitive landscape.
Highest ROE of 21.76% and strong growth metrics.
High profitability with an ROE of 16.63% and a decent growth rate.
Best revenue growth at 18.12% YoY, indicating strong market performance.